Comparison of sublingual buprenorphine and intravenous morphine in reducing bone metastases associated pain in cancer patients

Bone metastases is one of the most common causes of pain in cancer patients and have a significant effect on their quality of life. The most common symptom of bone metastases is pain that gradually develops. Morphine is used to relieve pain in these patients, but poorly accepted due to its adverse events. Therefore, the current study was aimed to compare the effect of sublingual buprenorphine, with certainly lower complications with morphine. Fourth patients were divided into 2 groups. In group A, metastatic cancer patients received 2.5 mg of intravenous morphine. Furthermore, in group B, sublingual tablet of buprenorphine (one-fourth of a 500 μg tablet) was administered sublingually. Pain was measured 15, 30, and 45 minutes after the onset of pain using visual analog scale ruler. Based on the obtained data, two groups A and B were compared using SPSS 23 software. There was a significant difference between the patient's pain intensity after 15 and 30 minutes from the onset of pain in both groups. Due to the fact that the duration of the effect of morphine is 3-4 hours and the duration of the effect of sublingual buprenorphine is 6-8 hours, morphine showed fast acting forms of opioids (P= 0.001). The required dose level on the first day was similar in both groups and there was no statistically significant difference between the two groups. While on the second and third days, the median dose in group A (morphine) was greater than group B (buprenorphine), indicating prolonged duration of action for buprenorphine compared with morphine, thus requiring lower subsequent doses. The results of this study suggested that sublingual buprenorphine is a higher effective drug compared to intravenous morphine during and after operation. With regard to easy and painless administration, it seems that its use can be useful in controlling pain due to bone metastases in cancer patients.

[1]  P. Friedmann,et al.  Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs , 2019, American journal of public health.

[2]  G. Noori,et al.  A comparative study on the prophylactic effects of paracetamol and dexmedetomidine for controlling hemodynamics during surgery and postoperative pain in patients with laparoscopic cholecystectomy , 2018, Medicine.

[3]  N. Mosaffa,et al.  Investigating Esophageal Stent-Placement Outcomes in Patients with Inoperable Non-Cervical Esophageal Cancer , 2018, Journal of Cancer.

[4]  H. Sørensen,et al.  Survival after bone metastasis by primary cancer type: a Danish population-based cohort study , 2017, BMJ Open.

[5]  P. Wiffen,et al.  Opioids for cancer pain - an overview of Cochrane reviews. , 2017, The Cochrane database of systematic reviews.

[6]  A. Agarwal,et al.  Use of corticosteroids for pain control in cancer patients with bone metastases: a comprehensive literature review , 2017, Current opinion in supportive and palliative care.

[7]  R. Ali,et al.  Buprenorphine for managing opioid withdrawal. , 2017, The Cochrane database of systematic reviews.

[8]  A. Gulia,et al.  Palliative Care in Musculoskeletal Oncology , 2016, Indian journal of palliative care.

[9]  S. Narod,et al.  The incidence of bone metastasis after early-stage breast cancer in Canada , 2016, Breast Cancer Research and Treatment.

[10]  P. Papagelopoulos,et al.  Modern Palliative Treatments for Metastatic Bone Disease: Awareness of Advantages, Disadvantages, and Guidance , 2016, The Clinical journal of pain.

[11]  L. Fallowfield,et al.  Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases , 2015, Supportive Care in Cancer.

[12]  H. Chin,et al.  Bone Metastasis: Concise Overview. , 2015, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[13]  M. Forootan,et al.  Adaptation of a Quality of Life Questionnaire for Iranian Patients with Esophageal Cancer , 2014, Indian journal of palliative care.

[14]  Young Ki Kim,et al.  Aspiration Pneumonitis Caused by Delayed Respiratory Depression Following Intrathecal Morphine Administration , 2012, The Korean journal of pain.

[15]  J. Gaertner,et al.  Cancer Pain Management and Bone Metastases: An Update for the Clinician , 2012, Breast Care.

[16]  M. Bosenberg,et al.  Decoding Melanoma Metastasis , 2010, Cancers.

[17]  T. Ali,et al.  EFFICACY OF MORPHINE INJECTION VERSUS SUBLINGUAL BUPRENORPHINE IN POSTOPERATIVE PAIN AFTER LUMBAR LAMINECTOMY , 2010 .

[18]  G. Vargas-Schaffer.  Is the WHO analgesic ladder still valid? Twenty-four years of experience. , 2010, Canadian family physician Medecin de famille canadien.

[19]  S. Eccles,et al.  Breast cancer metastasis: when, where, how? , 2005, The Lancet.

[20]  A. Beskow,et al.  Premedication with sublingual buprenorphine for out‐patient arthroscopy: reduced need for postoperative pethidine but higher incidence of nausea , 1995, Acta anaesthesiologica Scandinavica.

[21]  R. Houde,et al.  Clinical analgesic assay of sublingual buprenorphine and intramuscular morphine. , 1982, NIDA research monograph.

[22]  A. Masson.  Sublingual Buprenorphine versus Oral Dihydrocodeine in Post-Operative Pain , 1981, The Journal of international medical research.

[23]  P. Eghtesadi-Araghi,et al.  Pre-anesthetic administration of sublingual buprenorphine for postoperative analgesia after hemorrhoidectomy a clinical trial. , 2009 .

[24]  S. Reggio,et al.  [Continuous intravenous infusion with patient-controlled anesthesia for postoperative analgesia in cesarean section: morphine versus buprenorphine]. , 1989, Minerva anestesiologica.